Orphazyme didn't know buyer before negotiations began

US-based Kempharm, which is set to purchase embattled Orphazyme, was until negotiations began relatively unknown to the Danish firm, according to CEO Anders Vadsholt, who still calls this the best solution considering the firm’s current situation.
Photo: Orphazyme/PR
Photo: Orphazyme/PR
by christopher due karlsson, translated by daniel pedersen

Orphazyme, a listed company in Denmark that has been restructuring since in March, did not have any superficial knowledge of its potentially new US-based owner, Kempharm, before entering negotiations.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading